ChemoMetec (CPSE:CHEMM) has announced a change in financial leadership, with the board appointing Phillip Massie Price as chief financial officer from 3 August 2026, replacing outgoing CFO Kim Nicolajsen.
See our latest analysis for ChemoMetec.
ChemoMetec’s CFO transition comes after a mixed period for shareholders, with the stock posting a 36.6% 90 day share price return while year to date share price performance is down 36.3%, and the 1 year total shareholder return has declined 12.7%.
If this leadership change has you rethinking where you want exposure, it can help to broaden your search and look at other companies that may be better aligned with your criteria through the 106 top founder-led companies
ChemoMetec’s share price has swung sharply while a new CFO steps in and analysts see a higher price target. Is it worth paying today’s DKK 430, or does it make more sense to wait for a cheaper entry?
Price-to-Earnings of 42.3x: Is it justified for ChemoMetec?
At DKK430, ChemoMetec is trading on a P/E of 42.3x, which screens as expensive relative to both its own fair P/E estimate and peer group comparisons.
The P/E ratio compares the current share price with earnings per share and is a simple way to see how much investors are paying for each unit of profit. For ChemoMetec, a higher P/E suggests the market is attaching a rich value to its earnings, despite a recent period where 1 year total shareholder returns have declined 12.7%.
According to the checks provided, ChemoMetec looks expensive versus its estimated fair P/E of 19.9x. It also sits above the peer average of 17x and the Global Life Sciences industry average of 36.6x. That is a wide gap that implies investors are paying a premium multiple. The market could eventually re rate closer to the fair ratio if expectations change.
Explore the SWS fair ratio for ChemoMetec
Result: Price-to-Earnings of 42.3x (OVERVALUED)
However, ChemoMetec’s rich 42.3x P/E and a 36.3% share price decline year to date leave little room if sentiment or earnings expectations start to cool.
Find out about the key risks to this ChemoMetec narrative.
Another View on ChemoMetec’s DKK430 Share Price
The P/E discussion presents ChemoMetec as expensive, and the SWS DCF model points in the same direction. At DKK430, the stock sits above an estimated future cash flow value of DKK375.68. This indicates limited valuation cushion if sentiment weakens.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ChemoMetec for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 255 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With ChemoMetec's valuation signals pointing both to premium pricing and real concerns, you can move quickly and test the data against your own expectations. To weigh up the balance of potential upside and downside before you act, review the 2 key rewards and 2 important warning signs
Looking for more ChemoMetec investment ideas?
If ChemoMetec has you reassessing your opportunities, do not stop at one stock. Use focused screeners to spot ideas that better match your risk and return preferences.
- Target stability and potential value by reviewing companies flagged in the 299 resilient stocks with low risk scores that may better fit a cautious approach.
- Spot potential bargains with stronger fundamentals by checking the 255 high quality undervalued stocks before prices move away from your comfort zone.
- Build a watchlist of resilient businesses by scanning the solid balance sheet and fundamentals stocks screener (422 results) to avoid missing companies with healthier financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com